Edwards Lifesciences Corporation (EW) Given Buy Rating at BMO Capital Markets

Lloyd Doyle
September 13, 2017

Edwards Lifesciences Corporation (NYSE:EW) current has a Beta score of 0.64.

Several other institutional investors and hedge funds have also modified their holdings of EW.

Over the previous year, Edwards Lifesciences Corporation (NYSE:EW)'s stock has performed 0.46%. Ameriprise Financial Inc owns 11,444 shares or 0% of their United States portfolio. During recent trading, shares saw a move of 1.71% hitting a price of $115.13. Finally, First Bank & Trust boosted its position in shares of Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company's stock valued at $129,000 after acquiring an additional 219 shares in the last quarter.

Palo Alto Investors Llc increased Abiomed Inc (ABMD) stake by 1.02% reported in 2016Q4 SEC filing. The Pnc Financial Services Group Inc holds 1.30 million shares with $122.22M value, down from 1.35 million last quarter. Institutional investors own 83.81% of the company's stock.

Edwards Lifesciences Corporation (NYSE:EW) CEO Michael A. Mussallem sold 32,900 shares of the business's stock in a transaction dated Thursday, September 7th. The stock has a 50 day moving average price of $93.31 and a 200 day moving average price of $104.34. Horan Capital Advisors Llc who had been investing in Viacom Inc New for a number of months, seems to be less bullish one the $11.45B market cap company.

Edwards Lifesciences Corporation (EW) opened the session with a $113.51 price tag, later ranging from $113.27 to $115.42, the range at which the stock has traded at throughout the day. The stock of Edwards Lifesciences Corp (NYSE:EW) earned "Buy" rating by Bank of America on Wednesday, July 27. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.88 by $0.20. American Century Companies raised its stake in Edwards Lifesciences Corporation by 7.2% in the Q1. The business earned $739.40 million during the quarter, compared to the consensus estimate of $749.14 million. Financial Counselors has an ownership of 13,637 stocks of the medical analysis firms shares valued at $1,283,000 after scooping up an extra 282 stocks in the previous period. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. Equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year. The stock closing price is now trading downward to its 50 day moving average with change of -0.27%, escalated to its 20 day moving average with figure of 1.57% and above its 200 day moving average with value 11.54%. The transaction was disclosed in a document filed with the SEC, which is available at this link. JP Morgan maintained the stock with "Overweight" rating in Monday, April 11 report. The mean rating score for this stock is at 2.00. The disclosure for this sale can be found here. Insiders have sold 163,541 shares of company stock worth $18,712,719 in the last ninety days. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of USA and global trademark and copyright legislation. The original version of this piece can be accessed at https://weekherald.com/2017/09/12/edwards-lifesciences-corporation-ew-stake-lessened-by-roosevelt-investment-group-inc.html.

EW has been the subject of a number of recent analyst reports. Finally, BTIG Research restated a "buy" rating and issued a $110.00 target price on shares of Edwards Lifesciences Corporation in a report on Saturday, December 10th. It is down 15.41% since September 12, 2016 and is uptrending. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a "hold" rating to a "buy" rating and set a $127.00 price target for the company in a research report on Tuesday, May 16th. Cowen and Company reiterated an outperform rating and issued a $135.00 target price (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. The firm has "Buy" rating by Canaccord Genuity given on Monday, September 4.

In order to reach an opinion and communicate the value and volatility of a covered security, analysts research public financial statements, listen in on conference calls and talk to managers and the customers of a company, typically in an attempt to capture the findings for a research report. Edwards Lifesciences Corporation presently has an average rating of "Buy" and an average target price of $120.75.

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and fix products used to replace or fix a patient's diseased or defective heart valve.

Other reports by Iphone Fresh

Discuss This Article